Objective Myelin oligodendrocyte glycoprotein–immunoglobulin G (MOG-IgG) associated
disorder (MOGAD) often manifests with recurrent CNS demyelinating attacks. The optimal
treatment for reducing relapses is unknown. To help determine the efficacy of long-term
immunotherapy in preventing relapse in patients with MOGAD, we conducted a multicenter
retrospective study to determine the rate of relapses on various treatments. Methods We
determined the frequency of relapses in patients receiving various forms of long-term …

Myelin oligodendrocyte glycoprotein (MOG) immunoglobulin G (IgG)–associated disorder
(MOGAD) is a demyelinating disease with phenotypic variability that can manifest as optic
neuritis, transverse myelitis, acute disseminating encephalomyelitis, brainstem encephalitis,
or combinations of the above. Limited information exists on optimal long-term therapy,
particularly with regard to reducing recurrent attacks. This was a multicenter observational
retrospective case series of patients with MOGAD receiving immunotherapy that aimed to …